In 2000-2003, preclinical studies of the active substance of the product named Procont were conducted. They were held at the Accredited Toxicology Laboratory in Hungary.

We examined the active substance on five types of cancer: sarcoma, colorectal carcinoma, breast cancer, lymphoid leukemia, and melanoma. And we got positive results in all five areas.

In the course of our experiments, we tested three methods of taking the Procont active substance: subcutaneous, that is, in the form of an injection, intraperitoneal, and oral.

As a result, oral method was most effective. Therefore, it was decided to release this product in capsule form.

Also, we made the main conclusions, starting from two factors: the survival rate and the average tumor mass.